DK3102218T3 - Behandling af topiske og systemiske bakterieinfektioner - Google Patents

Behandling af topiske og systemiske bakterieinfektioner Download PDF

Info

Publication number
DK3102218T3
DK3102218T3 DK15703086.7T DK15703086T DK3102218T3 DK 3102218 T3 DK3102218 T3 DK 3102218T3 DK 15703086 T DK15703086 T DK 15703086T DK 3102218 T3 DK3102218 T3 DK 3102218T3
Authority
DK
Denmark
Prior art keywords
topic
treatment
bacteria infections
systemic
systemic bacteria
Prior art date
Application number
DK15703086.7T
Other languages
English (en)
Inventor
Michael Mattey
Emma Lisa Bell
Original Assignee
Fixed Phage Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fixed Phage Ltd filed Critical Fixed Phage Ltd
Application granted granted Critical
Publication of DK3102218T3 publication Critical patent/DK3102218T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00033Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10111Myoviridae
    • C12N2795/10132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15703086.7T 2014-02-07 2015-02-09 Behandling af topiske og systemiske bakterieinfektioner DK3102218T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1402139.8A GB201402139D0 (en) 2014-02-07 2014-02-07 Treatment of topical and systemic bacterial infections
PCT/EP2015/052635 WO2015118150A2 (en) 2014-02-07 2015-02-09 Treatment of topical and systemic bacterial infections

Publications (1)

Publication Number Publication Date
DK3102218T3 true DK3102218T3 (da) 2020-12-07

Family

ID=50390631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15703086.7T DK3102218T3 (da) 2014-02-07 2015-02-09 Behandling af topiske og systemiske bakterieinfektioner

Country Status (11)

Country Link
US (4) US20170020937A1 (da)
EP (1) EP3102218B1 (da)
JP (1) JP6736476B6 (da)
CN (1) CN106132440A (da)
AU (1) AU2015214135B2 (da)
CA (1) CA2937607C (da)
DK (1) DK3102218T3 (da)
ES (1) ES2835707T3 (da)
GB (1) GB201402139D0 (da)
PT (1) PT3102218T (da)
WO (1) WO2015118150A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
JP2020517735A (ja) * 2017-04-21 2020-06-18 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス(Propionibacterium acnes)バクテリオファージを含む組成物
BR112020010580A2 (pt) * 2017-12-05 2020-10-27 Biomx Ltd. tratamento bacteriofágico para acne e biofilmes
EP3852774A4 (en) 2018-06-29 2022-03-23 Tets, Viktor, Veniaminovich METHODS OF DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES
EP4337764A1 (en) 2021-05-12 2024-03-20 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
CN116159039A (zh) * 2023-02-21 2023-05-26 河北工业大学 一种破坏生物膜的近红外光响应共轭聚合物/噬菌体复合纳米粒子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918983D0 (en) 1989-08-21 1989-10-04 Unilever Plc Composition for hygiene purposes
US20020001590A1 (en) * 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
GB0207021D0 (en) 2002-03-25 2002-05-08 Univ Warwick Anti-bacterial agents
DE60315636T2 (de) 2002-03-25 2008-05-08 University Of Warwick, Coventry Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
MX2007005279A (es) * 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Composiciones de bacteriofagos.
US20100291537A1 (en) * 2004-11-16 2010-11-18 Glauco Souza Methods and compositions related to phage-nanoparticle assemblies
WO2007007055A1 (en) 2005-07-12 2007-01-18 The University Of Leeds Bacteriophage and their uses
GB0526176D0 (en) * 2005-12-22 2006-02-01 Blaze Venture Technologies Ltd Particle binding
WO2009108964A2 (en) * 2008-02-28 2009-09-03 Becker Leslie "zee" developmental plaything
GB201110647D0 (en) * 2011-06-23 2011-08-10 Fixed Phage Ltd Delivery of viral agents
GB201217097D0 (en) 2012-09-25 2012-11-07 Fixed Phage Ltd Treatment of bacterial infection

Also Published As

Publication number Publication date
CA2937607C (en) 2023-08-01
ES2835707T3 (es) 2021-06-23
JP6736476B6 (ja) 2020-12-16
US20210038658A1 (en) 2021-02-11
PT3102218T (pt) 2020-12-15
CA2937607A1 (en) 2015-08-13
US20170020937A1 (en) 2017-01-26
WO2015118150A3 (en) 2015-11-12
EP3102218B1 (en) 2020-09-09
CN106132440A (zh) 2016-11-16
WO2015118150A2 (en) 2015-08-13
US20210290703A1 (en) 2021-09-23
JP6736476B2 (ja) 2020-08-05
AU2015214135A1 (en) 2016-08-04
US20190350991A1 (en) 2019-11-21
JP2017505820A (ja) 2017-02-23
EP3102218A2 (en) 2016-12-14
GB201402139D0 (en) 2014-03-26
AU2015214135B2 (en) 2020-07-23
US11779618B2 (en) 2023-10-10

Similar Documents

Publication Publication Date Title
DK3291679T3 (da) Ændring af mikrobielle populationer og modificering af mikrobiota
DK3129018T3 (da) Behandling af NAFLD og NASH
DK3117310T3 (da) Håndtering af behandling associeret med valgte arkitektoniske indretninger
DK3653221T5 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3172213T3 (da) Makrocykliske kinasehæmmere og anvendelser deraf
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
GB2554629B8 (en) Prevention and treatment of microbial infections
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
SG11201609652RA (en) Treatment of polybacterials infections
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
DK3102218T3 (da) Behandling af topiske og systemiske bakterieinfektioner
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3131920T3 (da) Msp-nanoporer og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3484599T3 (da) Oprensningsfremgangsmåde og anvendelser deraf
DK3285787T3 (da) Behandling af bakterieinfektioner i akvakultur
DK3337506T3 (da) Kombinationer og anvendelser deraf